Latest Breaking News On - High throughput endocytosis platform - Page 1 : comparemela.com

- First clinical trial to evaluate the safety and efficacy of OBI-992 (a.k.a BSI-992), a novel antibody drug conjugate (ADC) targeting TROP2- Dosing of first

Hughm davisWayne savilleHeidi wangBiosion syntracerAdagloxad simoleninBiosion incPharma incBusiness developmentBiosion united states incDrug administrationHigh throughput endocytosis platformChief businessDevelopment officerBiosion united statesChief medical officerChief executive officer